ARHGEF18

Across TCGA pan-cancer cohorts, ARHGEF18 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ARHGEF18 data layer compared with 25 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ARHGEF18 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ARHGEF18 expression acts as an unfavorable survival marker, although some lineages such as PDAC and CCRCC show a favorable association.

PDAC, CCRCC, and LUAD are the cancer types where ARHGEF18 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Quartile	II,III,IV	0.611	0.307	.009	16	view →
CCRCC	DFS	Quartile	All	0.926	0.467	.005	13	view →
LUAD	DFS	Median	All	0.818	0.701	.034	3	view →
HNSC	OS	Median	III,IV	0.587	0.772	.038	1	view →
LSCC	DFS	Median	All	0.894	0.518	.032	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ARHGEF18–PDAC (DFS)

Open the PDAC breakdown →